Lenalidomide as salvage treatment for multiple myeloma relapsing

  • Slides: 7
Download presentation
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation:

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy by Tereza Coman, Emmanuel Bachy, Mauricette Michallet, Gérard Socié, Madalina Uzunov, Jean Henri Bourhis, Simona Lapusan, Alain Brebion, Stéphane Vigouroux, Sébastien Maury, Sylvie François, Anne Huynh, Bruno Lioure, Ibrahim Yakoub. Agha, Olivier Hermine, Noël Milpied, Mohamad Mohty, and Marie Thérèse Rubio haematol Volume 98(5): 776 -783 April 30, 2013 © 2013 by Ferrata Storti Foundation

Patients’ characteristics at baseline and at allo-SCT. Tereza Coman et al. Haematologica 2013; 98:

Patients’ characteristics at baseline and at allo-SCT. Tereza Coman et al. Haematologica 2013; 98: 776 -783 © 2013 by Ferrata Storti Foundation

Features of lenalidomide salvage therapy. Tereza Coman et al. Haematologica 2013; 98: 776 -783

Features of lenalidomide salvage therapy. Tereza Coman et al. Haematologica 2013; 98: 776 -783 © 2013 by Ferrata Storti Foundation

Response rates to lenalidomide after allo-SCT and assessment of influencing factors. Tereza Coman et

Response rates to lenalidomide after allo-SCT and assessment of influencing factors. Tereza Coman et al. Haematologica 2013; 98: 776 -783 © 2013 by Ferrata Storti Foundation

Evolution of patients after lenalidomide treatment. Tereza Coman et al. Haematologica 2013; 98: 776

Evolution of patients after lenalidomide treatment. Tereza Coman et al. Haematologica 2013; 98: 776 -783 © 2013 by Ferrata Storti Foundation

Occurrence of acute GVHD on lenalidomide treatment and assessment of influencing factors. Tereza Coman

Occurrence of acute GVHD on lenalidomide treatment and assessment of influencing factors. Tereza Coman et al. Haematologica 2013; 98: 776 -783 © 2013 by Ferrata Storti Foundation

Survival rates after lenalidomide introduction and assessment of influencing factors. Tereza Coman et al.

Survival rates after lenalidomide introduction and assessment of influencing factors. Tereza Coman et al. Haematologica 2013; 98: 776 -783 © 2013 by Ferrata Storti Foundation

Lenalidomide as salvage treatment for multiple myeloma relapsingLenalidomide as salvage treatment for multiple myeloma relapsing
Lenalidomide treatment for relapsedrefractory multiple myeloma the experienceLenalidomide treatment for relapsedrefractory multiple myeloma the experience
Multiple Myeloma Multiple Myeloma MM is a malignantMultiple Myeloma Multiple Myeloma MM is a malignant
Multiple Myeloma By Dr Sameh Shamaa Multiple MyelomaMultiple Myeloma By Dr Sameh Shamaa Multiple Myeloma
Multiple Myeloma Multiple Myeloma Definition Malignant proliferation ofMultiple Myeloma Multiple Myeloma Definition Malignant proliferation of
Multiple Myeloma Submitted 2015 Multiple Myeloma MM isMultiple Myeloma Submitted 2015 Multiple Myeloma MM is